HLS Therapeutics Ownership
HLTRF Stock | USD 2.33 0.10 4.12% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
HLS |
HLS Pink Sheet Ownership Analysis
About 64.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 1.86. Some equities with similar Price to Book (P/B) outperform the market in the long run. HLS Therapeutics recorded a loss per share of 0.37. The entity last dividend was issued on the 30th of January 2023. HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. HLS Therapeutics Inc. was founded in 2018 and is headquartered in Etobicoke, Canada. Hls Therapeutics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 92 people.The quote for HLS Therapeutics is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To learn more about HLS Therapeutics call Gilbert Godin at 647 495 9000 or check out https://www.hlstherapeutics.com.Currently Active Assets on Macroaxis
Other Information on Investing in HLS Pink Sheet
HLS Therapeutics financial ratios help investors to determine whether HLS Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HLS with respect to the benefits of owning HLS Therapeutics security.